European Commission Approves New Treatments for Urothelial and Lung Cancer

by EMA Approval | 30 August 2024 | Lung Cancer, Urogenital

The European Commission has approved two new cancer treatments: enfortumab vedotin in combination with pembrolizumab for urothelial cancer and amivantamab-vmjw in combination with chemotherapy for non-small cell lung cancer (NSCLC). These approvals mark significant...

EU to Approve Toripalimab for Advanced Head & Neck, & Zolbetuximab in GEJ cancer

by EMA Approval | 31 July 2024 | Gastrointestinal

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recently recommended the approval of several new treatments for advanced cancers, including toripalimab-tpzi for nasopharyngeal carcinoma (NPC) and esophageal squamous cell...

Swissmedic Approves Alectinib In Early Stage ALK+ NSCLC

by Swiss Approval | 26 July 2024 | Lung Cancer

Alectinib has been approved by the Swissmedic as a monotherapy for adjuvant treatment in adult patients with ALK-positive stage IB (tumor ≥4cm) to IIIA non-small cell lung cancer after complete tumor resection. The recommended dose is 600 mg twice daily. It is...

HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

by Ilaria Colombo | 19 July 2024 | Women's Cancers

Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...

Our New Partnership with Universimed and Leading Opinions

by PEAK Medicals | 17 July 2024 | OncoNews

We are thrilled to announce our new partnership with Universimed, a renowned medical publisher, and their esteemed journal, Leading Opinions. This collaboration marks a significant step forward in our commitment to advancing oncology education.  © OncoViews As part of...